COPD-Lower Respiratory Tract Infection Visual Analogue Score (c-LRTI-VAS) validation in stable and exacerbated patients with COPD

Prins, Hendrik J.; Duijkers, Ruud; Daniels, Johannes M.A.; Molen, Thys van der; Werf, Tjip S van der; Boersma, Wim

doi:10.1136/bmjresp-2020-000761

Cited by 1 publication

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Main study parameters include the daily assessment of respiratory symptoms, vital signs and pre-bronchodilator spirometry. The validated EXAcerbations of Chronic pulmonary disease Tool 48 and COPD-Lower Respiratory Tract Infection-Visual Analogue Score 49 will be administered for the standardised assessment of respiratory symptoms. Vital signs will be recorded at rest and include the assessment of systolic and diastolic blood pressure, heart rate, oxygen saturation, body temperature and breathing frequency.…”

Section: Methods and Analysismentioning

confidence: 99%

Early diagnostic BioMARKers in exacerbations of chronic obstructive pulmonary disease: protocol of the exploratory, prospective, longitudinal, single-centre, observational MARKED study

et al. 2023

View full text Add to dashboard Cite

IntroductionAcute exacerbations of chronic obstructive pulmonary disease (AECOPD) play a pivotal role in the burden and progressive course of chronic obstructive pulmonary disease (COPD). As such, disease management is predominantly based on the prevention of these episodes of acute worsening of respiratory symptoms. However, to date, personalised prediction and early and accurate diagnosis of AECOPD remain unsuccessful. Therefore, the current study was designed to explore which frequently measured biomarkers can predict an AECOPD and/or respiratory infection in patients with COPD. Moreover, the study aims to increase our understanding of the heterogeneity of AECOPD as well as the role of microbial composition and hostmicrobiome interactions to elucidate new disease biology in COPD.Methods and analysisThe ‘Early diagnostic BioMARKers in Exacerbations of COPD’ study is an exploratory, prospective, longitudinal, single-centre, observational study with 8-week follow-up enrolling up to 150 patients with COPD admitted to inpatient pulmonary rehabilitation at Ciro (Horn, the Netherlands). Respiratory symptoms, vitals, spirometry and nasopharyngeal, venous blood, spontaneous sputum and stool samples will be frequently collected for exploratory biomarker analysis, longitudinal characterisation of AECOPD (ie, clinical, functional and microbial) and to identify host–microbiome interactions. Genomic sequencing will be performed to identify mutations associated with increased risk of AECOPD and microbial infections. Predictors of time-to-first AECOPD will be modelled using Cox proportional hazards’ regression. Multiomic analyses will provide a novel integration tool to generate predictive models and testable hypotheses about disease causation and predictors of disease progression.Ethics and disseminationThis protocol was approved by the Medical Research Ethics Committees United (MEC-U), Nieuwegein, the Netherlands (NL71364.100.19).Trial registration numberNCT05315674.

show abstract

Section: Methods and Analysismentioning

confidence: 99%